View in EDS HTML Full Text PDF Full Text

Brief Report: Maternal Opioid Prescription from Preconception through Pregnancy and the Odds of Autism Spectrum Disorder and Autism Features in Children

Saved in:
Bibliographic Details
Title: Brief Report: Maternal Opioid Prescription from Preconception through Pregnancy and the Odds of Autism Spectrum Disorder and Autism Features in Children
Language: English
Authors: Rubenstein, Eric (ORCID 0000-0002-9146-4497), Young, Jessica C., Croen, Lisa A., DiGuiseppi, Carolyn, Dowling, Nicole F., Lee, Li-Ching, Schieve, Laura, Wiggins, Lisa D., Daniels, Julie
Source: Journal of Autism and Developmental Disorders. Jan 2019 49(1):376-382.
Availability: Springer. Available from: Springer Nature. 233 Spring Street, New York, NY 10013. Tel: 800-777-4643; Tel: 212-460-1500; Fax: 212-348-4505; e-mail: customerservice@springernature.com; Web site: https://link.springer.com/
Peer Reviewed: Y
Page Count: 7
Publication Date: 2019
Sponsoring Agency: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (NIH)
Contract Number: T32HD007489
U54HD090256
Document Type: Journal Articles
Reports - Research
Descriptors: Mothers, Narcotics, Autism, Pervasive Developmental Disorders, Pregnancy, Brain, Risk, Correlation, Drug Therapy, Case Studies, Prenatal Influences, Child Development
DOI: 10.1007/s10803-018-3721-8
ISSN: 0162-3257
Abstract: Opioid use during pregnancy is associated with suboptimal pregnancy outcomes. Little is known about child neurodevelopmental outcomes. We examined associations between maternal opioid prescriptions preconception to delivery (peri-pregnancy) and child's risk of ASD, developmental delay/disorder (DD) with no ASD features, or ASD/DD with autism features in the Study to Explore Early Development, a case-control study of neurodevelopment. Preconception opioid prescription was associated with 2.43 times the odds of ASD [95% confidence interval (CI) 0.99, 6.02] and 2.64 times the odds of ASD/DD with autism features (95% CI 1.10, 6.31) compared to mothers without prescriptions. Odds for ASD and ASD/DD were non-significantly elevated for first trimester prescriptions. Work exploring mechanisms and timing between peri-pregnancy opioid use and child neurodevelopment is needed.
Abstractor: As Provided
Number of References: 27
Entry Date: 2019
Accession Number: EJ1202711
Database: ERIC
Full text is not displayed to guests.
Description
Abstract:Opioid use during pregnancy is associated with suboptimal pregnancy outcomes. Little is known about child neurodevelopmental outcomes. We examined associations between maternal opioid prescriptions preconception to delivery (peri-pregnancy) and child's risk of ASD, developmental delay/disorder (DD) with no ASD features, or ASD/DD with autism features in the Study to Explore Early Development, a case-control study of neurodevelopment. Preconception opioid prescription was associated with 2.43 times the odds of ASD [95% confidence interval (CI) 0.99, 6.02] and 2.64 times the odds of ASD/DD with autism features (95% CI 1.10, 6.31) compared to mothers without prescriptions. Odds for ASD and ASD/DD were non-significantly elevated for first trimester prescriptions. Work exploring mechanisms and timing between peri-pregnancy opioid use and child neurodevelopment is needed.
ISSN:0162-3257
DOI:10.1007/s10803-018-3721-8